

山竺果壳的化学成分

胡江苗^{1,2}, 陈纪军¹, 赵友兴¹, 王睿睿³, 郑永唐³, 周俊^{1*}

(1 中国科学院昆明植物研究所植物化学与西部植物资源持续利用国家重点实验室, 云南 昆明 650204; 2 中国科学院研究生院, 北京 100039; 3 中国科学院昆明动物研究所分子免疫药理学实验室, 云南 昆明 650223)

摘要: 从山竺 (*Garcinia mangostana*) 果壳中分离得到 6 个化合物, 通过 MS, 1D NMR 以及与文献对照鉴定它们为 4 个呋喃类化合物: α -mangostin (1), β -mangostin (2), γ -mangostin (3), 5, 9-dihydroxy-8-methoxy-2, 2-dimethyl-7-(3-methylbut-2-enyl)-2H, 6H-pyrano-[3, 2-b]-xanthen-6-one (4), 以及表儿茶素 (epicatechin, 5) 和一个双苄类化合物 egonol (6)。其中化合物 5 和化合物 6 为首次从该植物中分离得到。对化合物 1~5 进行抗 HIV-1 RT 活性筛选结果表明, 化合物 2 和化合物 5 在浓度 200 $\mu\text{g/ml}$ 的条件下, 其对 HIV-1 RT 抑制率分别为 41.97% 和 47.72%; 同一实验结果显示化合物 1, 3 和 4 没有抑制 HIV-1 RT 作用。

关键词: 山竺; 呋喃; Egonol; 表儿茶素; 抗 HIV-1 RT 活性

中图分类号: Q 946

文献标识码: A

文章编号: 0253-2700(2006)03-319-04

Chemical Constituents from Fruit Hulls of *Garcinia mangostana* (Cuttiferae)

HU Jiang-Miao^{1,2}, CHEN Ji-Jun¹, ZHAO You-Xing¹, WANG Rui-Rui³,
ZHENG Yong-Tang³, ZHOU Jun^{1*}

(1 State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650204, China; 2 Graduate School of the Chinese Academy of Sciences, Beijing 100039, China; 3 Laboratory of Molecular Immunopharmacology, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China)

Abstract: From the fruit hulls of *Garcinia mangostana*, six known compounds were isolated and identified as α -mangostin (1), β -mangostin (2), γ -mangostin (3), 5, 9-dihydroxy-8-methoxy-2, 2-dimethyl-7-(3-methylbut-2-enyl)-2H, 6H-pyrano-[3, 2-b]-xanthen-6-one (4), epicatechin (5) and egonol (6) based on spectral analysis and by comparison with literature data. Compound 5 and 6 were isolated from this plant for the first time. Meanwhile, *In vitro* bioassay screening, the results indicated that β -mangostin (2) and epicatechin (5) showed inhibitory activities on recombinant HIV-1 RT with inhibitory percentage of 41.97 and 47.72 at 200 $\mu\text{g/ml}$. Compounds 1, 3 and 4 showed no inhibitory activities at the same bioassay.

Key words: *Garcinia mangostana*; Xanthone; Egonol; Epicatechin; Inhibitory activities on recombinant HIV-1 RT

Garcinia mangostana L. is commonly cultivated throughout south and southeast Asia where it is the source of the mangosteen fruits as well as been used for healing skin infections and wounds and for the relief of diarrhea. (Gopalakrishnan *et al*, 1997; Suksamram

et al, 2002). The fruit hulls of *G. mangostana* L. (Cuttiferae) are reported to be used as an anti-inflammatory agent and an astringent or used against diarrhea (Chairungsri *et al*, 1996). The main metabolites are xanthenes (Bennett and Lee, 1989) with α -man-

* Author for correspondence. Tel: 0871-5223264, Fax: 0871-5223261, E-mail: jzhou@mail.kib.ac.cn

Received date: 2005-09-21, Accepted date: 2005-10-21

作者简介: 胡江苗 (1979-) 男, 博士研究生, 主要从事天然产物化学研究。

gostin (1), β -mangostin (2) and γ -mangostin (3). In the course of screen on biologically active constituents, six known compounds (Fig. 1) were isolated from the fruit hulls of *G. mangostana* L. Their structures were identified based on spectral analysis and by comparison with literature data as α -mangostin (1) (Yates and Stout, 1958; Chen *et al.*, 1996), β -mangostin (2) (Yates and Bhat, 1968), γ -mangostin (3) (Govindachari *et al.*, 1971; Chen *et al.*, 1996), 5, 9-dihydroxy-8-methoxy-2, 2-dimethyl-7-(3-methylbut-2-enyl)-2H, 6H-pyrano-[3, 2-b]-xanthen-6-one (4) (Sen *et al.*, 1980), epicatechin (5) (Cui *et al.*, 2005; Gen, 1983) and egonol (6) (Takanashi and Takizawa, 1988). Compounds 1–4 were obtained as yellow powders, compounds 5–6 as

brown powders and were found in this plant for the first time. This paper describes the isolation and identification of this six compounds and the inhibitory activities on recombinant HIV-1 RT results of compounds 1–5. The results provided chemical and biological evidences for the further investigation on this plant.

In vitro bioassay screening, the results indicated that β -mangostin (2) and epicatechin (5) showed definite inhibitory activities on recombinant HIV-1 RT with inhibitory percentage of 41.97 and 47.72 at 200 μ g/ml, while α -mangostin (1), γ -mangostin (3) and 5, 9-dihydroxy-8-methoxy-2, 2-dimethyl-7-(3-methylbut-2-enyl)-2H, 6H-pyrano-[3, 2-b]-xanthen-6-one (4) showed no inhibitory activities at the same bioassay.




Fig. 1 Structures of compounds 1–6

Experimental

General experimental procedures Melting point was measured on a XRC-1 micro-melting point apparatus and was uncorrected. EI-MS were obtained on a VG Auto Spec-3000 mass spectrometer, 1D NMR spectra were obtained on a Bruker AV-400 MHz and a DRX-500 MHz spectrometer with TMS as internal standard. Si gel (200–300 mesh) for column chromatography and silica gel G for TLC were obtained from the Qindao Marine Chemical factory.

Plant material The fruit hulls of *Garcinia mangostana* L. were bought in the market in June 2003, Kunming, Yunnan

province. Identified by Dr. LEI Li-Gong, the main functionary of the herbarium, Kunming Institute of Botany, Chinese Academy of Sciences.

Extraction and Isolation The air-dried fruit hulls of *G. mangostana* L. (2.7 kg) were powdered and extracted with 80% EtOH (3 \times 6 L) under reflux for 3 h each time. The extracted EtOH (18 L) was evaporated under reduced pressure and suspended in water (1500 ml), then fractionated by successive portions with $CHCl_3$ (3 \times 1500 ml) and *n*-BuOH (3 \times 1500 ml) to give $CHCl_3$ -soluble (159.5 g) and *n*-BuOH-soluble (102.5 g) fractions. A portion (154.5 g) of the $CHCl_3$ -soluble fraction was

subjected to Si-gel column chromatography (200–300 mesh, 1400 g) and eluted with CHCl_3 -MeOH (100:0, 98:2, 95:5, 90:10, 80:20, 70:30, 0:100, v/v) gradient solvent system repeatedly to afford **1** (30 g), **2** (3 g), **3** (5 g), **4** (1 g) and **6** (30 mg). A portion (10 g) of the n-BuOH-soluble fractions was subjected to Si-gel column chromatography (200–300 mesh, 200 g) and eluted with petroleum ether-acetone (75:25, v/v) to afford compound **5** (100 mg).

α -mangostin (1), $\text{C}_{24}\text{H}_{26}\text{O}_6$, yellow powder, mp 182–183°C, EI-MS m/z (%): 410 ($[\text{M}]^+$, 51), 339 (100), 162 (23); ^1H NMR (400 MHz, CDCl_3) δ : 6.71 (1H, s, H-5), 6.25 (1H, s, H-4), 5.28 (1H, t, $J=6.5$ Hz, H-2'), 5.26 (1H, t, $J=5.8$ Hz, H-2''), 4.10 (1H, d, $J=5.8$ Hz, H-1''), 3.78 (3H, s, 7-OCH₃), 3.36 (2H, d, $J=6.5$ Hz, H-1'), 1.83 (3H, s, H-5''), 1.81 (3H, s, H-5'), 1.69 (3H, s, H-4''), 1.69 (3H, s, H-4'); ^{13}C NMR (100 MHz, CDCl_3) δ : 181.8 (s, C-9), 161.6 (s, C-3), 160.1 (s, C-6), 155.5 (s, C-10a), 155.3 (s, C-1), 154.7 (s, C-4a), 142.9 (s, C-7), 137.1 (s, C-8), 131.8 (s, C-3'), 131.4 (s, C-3''), 123.3 (d, C-2''), 122.2 (d, C-2'), 111.4 (s, C-8a), 109 (s, C-2), 102.9 (s, C-9a), 101.6 (d, C-5), 92.2 (d, C-4), 60.9 (q, C-7-OCH₃), 26.1 (t, C-1''), 25.5 (q, C-4''), 25.5 (q, C-4'), 21.2 (t, C-1'), 17.8 (q, C-5''), 17.5 (q, C-5'). (Yates and Stout, 1958; Chen *et al*, 1996).

β -mangostin (2), $\text{C}_{25}\text{H}_{28}\text{O}_6$, yellow powder, mp 175–176°C, EI-MS m/z (%): 424 ($[\text{M}]^+$, 91), 381 (34), 353 (100); ^1H NMR (500 MHz, CDCl_3) δ : 6.60 (1H, s, H-5), 6.17 (1H, s, H-4), 5.11 (1H, t, $J=6.4$ Hz, H-2''), 5.07 (1H, t, $J=7.1$ Hz, H-2'), 3.95 (1H, d, $J=6.4$ Hz, H-1''), 3.74 (3H, s, 3-OCH₃), 3.65 (3H, s, 7-OCH₃), 3.18 (2H, d, $J=7.1$ Hz, H-1'), 1.69 (3H, s, H-5''), 1.64 (3H, s, H-5'), 1.54 (3H, s, H-4''), 1.53 (3H, s, H-4'); ^{13}C NMR (100 MHz, CDCl_3) δ : 181.8 (s, C-9), 163.1 (s, C-3), 159.1 (s, C-6), 155.9 (s, C-10a), 155.3 (s, C-1), 155.0 (s, C-4a), 143.1 (s, C-7), 137.1 (s, C-8), 131.3 (s, C-3''), 131.3 (s, C-3'), 123.3 (d, C-2''), 122.1 (d, C-2'), 111.3 (s, C-8a), 110.9 (s, C-2), 103.5 (s, C-9a), 101.6 (d, C-5), 88.6 (d, C-4), 60.7 (q, C-7-OCH₃), 55.4 (q, C-3-OCH₃), 26.0 (t, C-1''), 25.4 (q, C-4''), 25.4 (q, C-4'), 21.0 (t, C-1'), 17.8 (q, C-5''), 17.3 (q, C-5'). (Yates and Bhat, 1968).

γ -mangostin (3), $\text{C}_{23}\text{H}_{24}\text{O}_6$, yellow powder, mp 207°C, EI-MS m/z (%): 396 ($[\text{M}]^+$, 91), 353 (59), 325

(100), 296 (91); ^1H NMR (500 MHz, CDCl_3) δ : 6.68 (1H, s, H-5), 6.23 (1H, s, H-4), 5.28 (1H, t, $J=5.8$ Hz, H-2''), 5.24 (1H, t, $J=6.2$ Hz, H-2'), 4.12 (1H, d, $J=5.8$ Hz, H-1''), 3.31 (1H, d, $J=6.2$ Hz, H-1'), 1.86 (3H, s, H-5''), 1.80 (3H, s, H-5'), 1.68 (3H, s, H-4''), 1.68 (3H, s, H-4'); ^{13}C NMR (100 MHz, CDCl_3) δ : 183.5 (s, C-9), 163.3 (s, C-3), 161.5 (s, C-6), 156.2 (s, C-10a), 154.0 (s, C-1), 153.1 (s, C-4a), 142.0 (s, C-7), 131.7 (s, C-8), 131.6 (s, C-3''), 129.5 (s, C-3'), 124.8 (d, C-2''), 123.9 (d, C-2'), 112.2 (s, C-8a), 111.1 (s, C-2), 103.8 (s, C-9a), 100.9 (d, C-5), 92.9 (d, C-4), 26.6 (t, C-1''), 26.1 (q, C-4''), 26.0 (q, C-4'), 22.2 (t, C-1'), 18.3 (q, C-5''), 17.9 (q, C-5'). (Govindachari *et al*, 1971; Chen *et al*, 1996).

5, 9-dihydroxy-8-methoxy-2, 2-dimethyl-7-(3-methylbut-2-enyl)-2H, 6H-pyrano-[3, 2-b]-xanthen-6-one (4), $\text{C}_{24}\text{H}_{24}\text{O}_6$, yellow powder, mp 156–157°C, EI-MS m/z (%): 408 ($[\text{M}]^+$, 51), 393 (100), 365 (44); ^1H NMR (400 MHz, CDCl_3) δ : 6.64 (1H, d, $J=10$ Hz, H-4), 6.62 (1H, s, H-10), 6.11 (1H, s, H-12), 5.47 (1H, d, $J=10$ Hz, H-3), 5.16 (1H, d, $J=6.0$ Hz, H-2'), 3.99 (2H, d, $J=6.0$ Hz, H-1'), 3.69 (3H, s, 8-OCH₃), 1.74 (3H, s, H-5'), 1.58 (3H, s, H-4'), 1.37 (3H, s, H-13), 1.37 (3H, s, H-14); ^{13}C NMR (100 MHz, CDCl_3) δ : 181.9 (s, C-6), 160.2 (s, C-12a), 157.7 (s, C-5), 156.1 (s, C-11a), 156.1 (s, C-9), 155.4 (s, C-10a), 143.2 (s, C-8), 137.2 (s, C-7), 131.6 (s, C-3'), 126.9 (d, C-3), 123.2 (d, C-2'), 115.5 (d, C-4), 112.8 (s, C-6a), 104.2 (s, C-4a), 103.5 (s, C-5a), 101.9 (d, C-10), 93.9 (d, C-12), 77.8 (s, C-2), 60.9 (q, C-8-OCH₃), 28.0 (q, C-13), 28.0 (q, C-14), 26.1 (q, C-1'), 25.6 (q, C-5'), 17.9 (q, C-4'). (Sen *et al*, 1980).

Epicatechin (5), $\text{C}_{15}\text{H}_{14}\text{O}_6$, white powder, mp 246–247°C, EI-MS m/z (%): 290 ($[\text{M}]^+$, 15), 152 (44), 139 (100), 123 (36); ^1H NMR (400 MHz, CD_3OD) δ : 6.97 (1H, d, $J=2.0$ Hz, H-2'), 6.80 (1H, d, $J=8.0$ Hz, H-5'), 6.76 (1H, dd, $J=8.0, 2.0$ Hz, H-6'), 5.95 (1H, d, $J=2.0$ Hz, H-8), 5.93 (1H, d, $J=2.0$ Hz, H-6), 4.80 (1H, brs, H-2), 4.17 (1H, m, H-3), 2.85 (1H, dd, $J=17.0, 4.5$ Hz, H-4), 2.75 (1H, dd, $J=17.0, 3.0$ Hz, H-4); ^{13}C NMR (100 MHz, CD_3OD) δ : 158.0 (s, C-5), 157.6 (s, C-7), 157.3 (s, C-9), 145.9 (s, C-3'), 145.7 (s, C-4'), 132.3 (s, C

-1'), 119.5 (d, C-6'), 116.0 (d, C-2'), 115.3 (d, C-5'), 100.2 (s, C-10), 96.6 (d, C-6), 96.0 (d, C-8), 79.8 (d, C-2), 67.5 (d, C-3), 29.2 (t, C-4). (Cui *et al.*, 2005; Gen, 1983).

Egonol (6), $C_{14}H_{18}O_5$, white powder, mp 117.5–118°C, EI-MS m/z (%): 326 ($[M]^+$, 62.5), 281 (100); 1H NMR (400 MHz, $CDCl_3$) δ : 7.59 (1H, dd, $J = 8.1$, 1.5 Hz, H-6'), 7.51 (1H, s, H-3), 7.15 (1H, d, $J = 1.5$ Hz, H-2'), 7.11 (1H, s, H-4), 7.08 (1H, d, $J = 8.1$ Hz, H-5'), 6.90 (1H, s, H-6), 6.18 (2H, s, O-CH₂-O), 3.48 (3H, s, 7-OCH₃), 3.77 (2H, t, $J = 6.4$ Hz, H-3''), 2.92 (2H, t, $J = 8.0$ Hz, H-1''), 2.06 (2H, m, H-2''); ^{13}C NMR (100 MHz, $CDCl_3$) δ : 157.2 (s, C-2), 149.7 (s, C-3'), 149.5 (s, C-4'), 146.2 (s, C-7), 139.3 (s, C-7a), 139.3 (s, C-5), 132.4 (s, C-3a), 126.2 (s, C-1'), 120.0 (d, C-6'), 113.5 (d, C-4), 109.6 (d, C-5'), 108.7 (d, C-6), 106.1 (d, C-2'), 102.8 (t, O-CH₂-O), 101.5 (d, C-3), 62.3 (t, C-3''), 56.0 (q, 7-OCH₃), 36.0 (t, C-1''), 33.4 (t, C-2''). (Takanashi and Takizawa, 1988).

Bioactive Assay Procedure

The inhibition of recombinant HIV-1 RT activity was performed with a commercially available ELISA kit (Boehringer Mannheim, Germany) according to the instructions of the manufacturer. Five serial dilutions of samples in DMSO (6 μ l) in duplicate were added to the reaction mixture. The final DMSO concentration used was 10%. The highest concentration of compounds was 200 μ g/ml. The compounds-free but contained an equivalent volume of DMSO were performed as control assays. Foscarnet was used as positive a control compound, it inhibited 100% of the HIV-1 RT activity at 100 μ g/ml. The inhibition percentage of the compounds was calculated.

Acknowledgements: The authors are grateful to the Analytical Group, Laboratory of Phytochemistry, Kunming Institute of Botany, CAS for the spectral measurements.

References:

- Bennett GJ, Lee HH, 1989. Xanthenes from guttiferæ [J]. *Phytochemistry*, **28**: 967–998
- Chairungsrikerd N, Takeuchi K, Ohizumi Y, *et al.*, 1996. Mangostanol, a prenyl xanthone from *Garcinia mangostana* [J]. *Phytochemistry*, **43**: 1099–1102
- Chen SX, Wan M, Loh BN, 1996. Active constituents against HIV-1 protease from *Garcinia mangostana* [J]. *Planta Med*, **62**: 381–382
- Cui YJ (崔艳君), Liu P (刘屏), Chen RY (陈若芸), 2005. Studies on the active constituents in vine stem of *patholobus suberectus* [J]. *China Journal of Chinese Materia Medica* (中国中药杂志), **30** (2): 121–123
- Gen-ichiro N, 1983. A new class of dimeric flavan-3-ol gallates, theasinensins A and B, and proanthocyanidin gallates from green tea leaf [J]. *Chem Pharm Bull*, **31** (11): 3906–3914
- Gopalakrishnan G, Banumathi B, Suresh C, 1997. Evaluation of the antifungal activity of natural xanthenes from *Garcinia mangostana* and synthetic derivatives [J]. *J Nat Prod*, **60**: 519–524
- Govindachari TR, Kalyanaraman PS, Muthukumaraswamy N, *et al.*, 1971. Isolation of three new xanthone from *Garcinia mangostana* [J]. *Indian J Chem*, **9**: 505–506
- Sen AK, Sarkar KK, Mazumder PC, *et al.*, 1980. A xanthone from *Garcinia mangostana* [J]. *Phytochemistry*, **19**: 2223–2225
- Suksamrarn S, Suwannapoch N, Ratananukul P, *et al.*, 2002. Xanthenes from the green fruit hulls of *Garcinia mangostana* [J]. *J Nat Prod*, **65**: 761–763
- Takanashi M, Takizawa Y, 1988. New benzofurans related to egonol from immature seeds of *Styrax obassia* [J]. *Phytochemistry*, **27** (4): 1224–1226
- Yates P, Bhat HB, 1968. Structure of β -mangostin [J]. *Can J Chem*, **46**: 3770–3772
- Yates P, Stout GH, 1958. The structure of mangostin [J]. *J Am Chem Soc*, **80**: 1691–1699